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PO LYCYTH AEM IA
A. W . D ELLIPIA N I, M .B., M.R.C.P.E.
Lecturer, U niversity Departm ent of Therapeutics, Royal Infirm ary, Edinburgh.
T h o u g h  strictly  speaking p olycyth aem ia  
m eans an increase in a ll th ree  form ed  elem ents 
in th e periph eral b lo od  the term  is usually  used 
to d escribe  an increase ab ove  norm al in the 
nu m b er o f c ircu latin g  red cells per un it vo lum e 
o f b lood . T h e  p o lycyth aem ia  m ay be relative, 
due to a fall in the p lasm a vo lu m e, or true 
or absolu te  w hen the total n u m ber o f red cells 
in the b ody, the red cell m ass, is increased. 
Such  an increase in the m ass o f c ircu latin g  red 
cells could  in theory be  p roduced  by a p ro long­
ation of the average life  span o f red cells be­
yond the norm al value  o f abou t n o  days, or 
by an increased ou tp u t o f red cells b y  the 
h aem o p o ie tic  system . P resen t evid ence in d i­
cates that in the m ajority  o f true polvcy- 
th acin ic  syndrom es, it is the latter w hich 
occurs (P ike 19 58).
SOME COMMENTS ON AETIOLOGY AND 
PATHOGENESIS
B efo re  d iscussing this fu rth er a b rie f word 
abou t the norm al con tro l o f erythropoicsis 
w ould  seem  appropriate. In  h ea lth  the num ­
ber o f  red cells in the b lood  stream  rem ains 
rem arkably con stan t and though it is know n 
that end ocrine  secretions from  th e gonads, the 
thyroid  and the suprarenals have considerable 
in fluence on this, they do n ot seem  to supply 
the fu n d am en tal stim u lu s to crythropoiesis 
(W in tro b e  19 6 1) .  F o r  m an y years, how ever, 
c lin ical and experim en tal observations in m an 
and anim als h ave show n the im portan ce o f 
oxygen; thus oxygen lack  has a stim ulating
effect and excess o f oxygen  depresses crythro­
poiesis. T h a t  this is n ot a d irect effect on 
eryth rop oiesis was show n by the fact that in 
p arab iotic  rats eryth rop oiesis occurs in both 
rats even if on ly  one o f them  is m ade anoxic 
(R eissm an n  1 960) and it can also be shown 
that the plasm a o f an aem ic an im als contains 
a factor capable o f s tim u latin g  erythropoiesis. 
T h is  and sim ilar w ork supported  earlier sug­
gestions o f the existence in the blood of a 
horm one-like substance capable  o f stim ulating 
e ryth rop oiesis. T h is  factor, erythropoietin , is 
now  usually  accepted  as the m ain humoral 
m echanism  in the contro l of eryth rop oiesis. It 
has no effect on leucocytes and platelets. The 
m ain source o f eryth rop oietin  is probably the 
k id n ey  b u t an extra renal site  o f this or a 
sim ilar h orm on e, p robab ly  in the liver, exists 
also (R o sse  and W a ld m a n n  19 62).
U n d er norm al cond itions it is presum ed that 
the oxygen tension in the b lood  controls the 
release of eryth rop oietin  w hich  is capable of 
stim u latin g  the m arrow  to produce red cells 
on ly. A n y  rise of the n u m ber o f red cells 
above norm al is coun teracted  by the tendency 
for such a change to depress the output of 
eryth ropoietin .
POLYCYTHAEMIA VERA
T h is  is the earliest o f these conditions to be 
described. O rig in a l d escriptions arc those of 
Vaquez (18 9 2 ) and Osler ( 19 0 3). In  contrast 
to the o th er p o lycyth aem ic syndrom es to be 
discussed, in the classical case there is evidence
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of hyperplasia o f all m arrow  elem ents, with 
leucocytosis and throm bocytosis in addition to 
erythrocytosis, and also splenom egaly.
The aetio logy is a su b ject w hich gives rise 
to much discussion and though m any would 
agree with the view  put forw ard b y  D am ash ek 
(1954) that it is a  relatively benign neoplasm , 
there lias been a tendency to challenge this in 
the light o f the recent progress m ade in the 
field of secondary polycythacm ias (P ike 1958). 
The neoplastic concept classifies polycythaem ia 
vera as one o f the group o f “ m yeloproliferative 
syndromes”  w hich includes m yelofibrosis, 
chronic m yeloid  leukaem ia, prim ary throm bo- 
cythaem ia and di G u g liem o ’s syndrom e, all 
these conditions being thought to have com ­
mon ancestry in the prim itive  m u ltip o tential 
mesench ym al cell. In favour o f this concept 
is the fact that interm ediate form s w ith feat­
ures characteristic o f several o f the clinical 
entities con stitu tin g the group m ay be seen 
quite frequ en tly  in the sam e p atien t and that 
one condition m ay evolve into another (Lopas 
and Jo sephson, 1964). A n  increase in basophil 
granulocytes is a com m on feature in these 
conditions w hich also appear to respond to the 
same type of therapy. M u ch  of the evidence 
in support o f the m yeloproliferative  concept 
of the aetio logy o f p olycythaem ia vera it w ill 
be appreciated , is largely circum stantial and 
other aetio logical possibilities w ill be m en tio n ­
ed later.
SE CONDARY P O L Y C Y T H A E M I A
In the ligh t of the know n physio logical im ­
portance o f oxygen in the contro l o f crythro- 
poiesis it is not surprising that a group o f well 
defined conditions exist w here tissue anoxia due 
to a low  oxygen saturation in the blood results 
in polycythaem ia. T h is  m ay result from  a low  
oxygen tension in the inspired air as occurs for 
example as part o f the adaptive m echanism  to 
high altitude. Path o logical causes include 
various diseases o f the lungs and heart, 
especially congenital cyanotic heart disease and 
arterio-venous shunts w hich a llow  unsaturated 
venous blood to enter the arterial circulation . 
H ypoventilation not necessarily due to lung 
disease as caused by extrem e obesity or struc­
tural chest disease, m ay also cause secondary 
polycythaem ia w hich m ay also result from  the 
presence o f abnorm al blood pigm ents.
In 19 45  F a ir ly  described tw o cases o f poly­
cythaemia treated by rem oval o f a renal car­
cinoma and subsequent developm ents have 
confirmed the association o f polycythaem ia
w ith various w ell defined lesions o f the k idney, 
benign and m alignant tum ours, cysts and 
h ydronephrosis, and o f other organs also, such 
as cerebellar h aem angioblastom a, phaeochrom o- 
cytom a, h epatom a and possib ly certain  uterine 
tum ours (P ike 19 38 ). T h e  association is p ar­
ticularly strong w ith  h ypernephrom a and p o ly ­
cythaem ia w ill be found in abou t 30-50 per 
cen t o f patients suffering from  this condition  
(P enington 19 65). Raised levels o f eryth ro­
p oietin  m ay be found  in the plasm a o f patients 
with anoxic polycyth aem ia and in patients 
w ith  renal lesions, cerebellar h aem angioblas­
tom a and phaeoch rom ocytom a (G u rn ey  19 6 5 , 
M od an  19 65).
P o lycythaem ia has also been noted to arise 
as a result o f the action o f various poisons. 
T h e  best evidence for such a causation is the 
p olycythaem ia w hich m ay fo llow  cobalt poison­
ing. T h is  is n ot related to the crythrocytosis 
w hich m ay fo llow  the treatm ent o f pernicious 
anaem ia. F o r  fu rth er in form ation  on this 
subject the reader should consult a recent re­
view  by M od an  (196 5).
In the ligh t o f the know n causes of second­
ary p olycythaem ia the possible roles o f anoxia 
and erythropoietin  in the aetio logy of p o ly­
cythaem ia ve ra have been scrutinised  recently 
and although anoxia seem s to h ave been ex­
cluded w ith out d ifficulty, the status o f erythro­
poietin  in p olycythaem ia v era rem ains unde­
cided (G u rn ey  19 6 5). I f  the red cell p rod uc­
tion in p olycythaem ia vera is due to prim ary 
p roliferation  in the bone m arrow  as suggested 
by the m yelo p ro liferation con cept o f the 
disorder one w ould expect the scrum  levels o f 
erythropoietin  to be depressed in that con­
d ition . U n fo rtu n ate ly  the m easurem ent o f 
erythropoietin  depends on b io logical assay 
m ethods which arc relatively crude. T h u s 
anyth in g less than a tw ofold  rise in the 
c ircu lating level o f erythropoietin  cannot be 
reliably detected  and it is know n that less than 
this is capable of p roducing polycythaem ia 
(P enington 19 65). I t  is also know n that the 
sen sitiv ity  o f d ifferent individuals to erythro­
poietin varies. E ven  the best m ethods at 
present available are only able to dem onstrate 
equivocal levels in norm al m an. I t  seem s 
therefore that present m ethods cannot defin­
itely  exclude raised erythropoietin  levels in 
polycy thaem ia vera and certain ly cannot 
dem onstrate reduced levels. H ow ever, even if 
erythropoietin  could be  im plicated  as a caus­
ative feature o f the erythrocy tosis o f poly­
cythaem ia vera, som e other horm one w ould
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have to be responsible for the leukocytosis and 
thrombocytosis com m only associated with that 
condition.
Another approach to the problem has been 
to see if there is any association between 
polycythaemia vera and any of the lesions 
known to be responsible for secondary poly­
cythaemia. D elam ore and M acdonald (1962) 
in a study of patients with polycythaemia vera, 
dem onstrated no pyclographic abnorm ality 
but Brandt and his colleagues (1963) in a larger 
scries of patients with polycythaemia vera 
found that 9 per cent of eases had significant 
lesions with included two renal carcinomas.
BENIGN ERYTHROCYTOSIS
In dealing with polycythaemia one is left 
with a group of patients with true poly­
cythaemia w ithout leukocytosis or throm bo­
cytosis and without splenomegaly. I n all 
respects the blood picture simulates that of 
secondary polycythaemia yet there is no 
clinical or laboratory evidence to support this. 
If. has been suggested (M odan 1965) that this 
group should be classified separately. Som e 
of these patients turn out to have poly- 
cythaemia vera and some perhaps to have poly­
cythaemia secondary to an unrecognised cause . 
M ost of the so-called eases of polycythaemia 
vera described in children belong in this group 
(Abildgaard et al 1964). Fam ilial cases 
associated with splenom egaly can be classified 
here. Som e individuals with erythrocytosis of 
this type may be cases with high normal blood 
counts. Apart from those patients who turn 
out to have polycythaemia vera,.. the main 
characteristic of this group of conditions is 
their benign course.
RELATIVE POLYCYTHAEMIA
In this condition the red cell values appear 
to be raised but are in fact normal or even 
reduced. T h e  apparently high counts arc the 
result of a considerably diminished plasma 
volume. In most cases the cause of this 
haemo-concentration such as burns, diuresis, 
dehydration, is obvious. In 1952 Lawrence 
and Berlin described a group of cases in 
which the red cell mass was normal and 
the plasma volum e chronically depressed 
giving rise to apparent erythrocytosis. T h ey 
called this polycythaem ia o f stress m ainly be­
cause the haemo-concentration simulated that 
which occurs initially on being exposed to the
stress of high altitude (Lawrence 1952). Dama- 
shek (1953) em phasised the association of this 
condition with anxiety and tension, vascular 
disease, hypertension and peptic ulceration 
In that the association with stress is only 
inferred the condition is probably better 
labelled as pseudopolycythaemia; there is well 
documented evidence that it is not uncommon 
and certainly com m oner than polycythaemia 
vera. It runs a more benign course and like 
polycythaem ia vera is com m oner in men.
It is likely that m any of the cases of poly- 
cy thacmia hypertonica which G aisbock de­
scribed belong to this group (Gaisbock 1922). 
T h is  interesting group is the subject of two 
recent reviews where it was found that 
although some patients with the features of 
G aisbock’s syndrome had a true though mild 
polycythaem ia, m any had pseudopolycythaemia 
(Russell and C onley 1964; H all 1965).
In the light of the preceding discussion the 
follow ing classification somewhat modified 
after M odan (1965) is suggested.
TABLE 1
True Polycythaemia
1. Polycythaemia vera.
2. Secondary Polycythaemia.
(a) Anoxic 
High altitude 
Lung Disease
Heart Disease-—-congenital 
or acquired 
Respiratory disease 
Obesity
Abnormal haemoglobin 
pigments
(b) Humoral 
Renal
Cerebellar haemangio- 
blastoma 
Phaeochromocytoma 
Uterine myoma (?)
Liver carcinoma 
Endocrine— Cushing’s 
syndrome 
Others
(c) Chemical and Toxic
3. Benign erythrocytosis
Idiopathic
Familial
Primary erythrocytosis of children 
Normal variant.
Relative Polycythaemia
1. Fluid loss or diminished intake.
2. Pseudopolycythaemia or polycythaemia of
stress.
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diagnosis
Space does not perm it a full description of 
the clinical features of these conditions. C er­
tain diagnostic difficulties arc worth discussion. 
The main problems which often arise can be 
stated as (a) Does the patient have poly­
cythaemia and (b) if so, is this true or relative 
polycythaemia, and, if the former, is the 
physician dealing with polycythaem ia vera or a 
secondary type?
Laboratory determ inations will usually en­
able the diagnosis of polycythaem ia to be made 
and a packed cell volum e of > 5 5 %  ( > 5 2 % 
in the female) establishes the diagnosis. H ow ­
ever, this may be masked in true polycythaem ia 
by the fact that the red cells tend to be small. 
Determination of the red cell count will dis­
tinguish these cases. Occasionally the plasma 
volume may rise in proportion to the red cell 
mass masking both the rise in the red cell 
count and the packed cell volume. T h e  reason 
for this may not be obvious but a not unusual 
cause is congestive cardiac failure. Bleeding, 
a com mon com plication of polycythaem ia 
vera for exam ple where there is a bleeding 
tendency and where 10 -15  p e r  c e n t  of 
patients have a peptic ulcer, may also mask 
the diagnosis. In difficult cases clinical sus­
picion may only be confirmed by an actual 
measurement of the red cell mass. T h e  most 
popular method of doing this is with the use 
of the radioactive isotope chrom ium   51 (M olli- 
son 19 6 1).
If in association with polycythaem ia there is 
leukocytosis, thrombocytosis, splenomegaly, 
hyperplasia of red and white cell and platelet 
precursors in the bone marrow and a raised 
leukocyte alkaline phosphatase, then the 
patient has polycythaem ia vera. A ll cases are, 
however, not typical. T h u s about 30 per cent 
of cases may have normal white and platelet 
counts and in a similar proportion the spleen 
is not palpable. T h e  marrow is not always 
hyperplastic. It  is in this group that the possi­
bility that one is dealing with pseudopoly- 
cythaemia arises and once this has been ex­
cluded by determ ining the red cell mass, 
secondary polycythaem ia is likely.
Though an anoxic polycythaem ia is usually 
clinically obvious this is not always so and in 
particular a pulm onary arterio-venous shunt 
may be overlooked. Determ ination of the per­
centage oxygen saturation of the arterial blood 
is the only way of excluding this group with 
certainty. T h is should norm ally be not less
than 9 7% . In older patients w ith poly­
cythaem ia vera levels of 9 3%  have been de­
scribed. T h ere are some cases of poly­
cythaemia vera however where unexplained 
levels of 9 1%  have been found. A  low level 
in this condition may occasionally be due to 
a throbotic com plication in the central nervous 
system resulting in hypoventilation (Bader et al 
1963). Intravenous pyelography and occasion­
ally aortagraphy will be necessary to dis­
tinguish renal causes of polycythaem ia and in 
fact in view of the findings of Brandt and his 
colleagues (1963) should be considered even in 
typical cases of polycythaemia vera. T h e  leuko­
cyte alkaline phosphatase is of considerable 
help in distinguishing vera from secondary 
types of polycythaem ia. In the latter cases it 
is not raised. Infection should be rem em ber­
ed however as one of the com m oner con­
ditions giving rise to abnorm ally high levels 
(H ayhoc 1958). A t present the determ ination 
of the circulating level of erythropoietin is too 
difficult and too insensitive to be used routine­
ly in diagnosis but should be considered in 
selected cases.
Som e eases will defeat all attem pts at an 
accurate diagnosis particularly when facilities 
for red cell mass determ ination are not avail­
able. Observation over a period o f time with 
perhaps appraisal of the response to careful 
venesection will help in m ost cases.
COURSE AND PROGNOSIS
T hough cases of polycythaem ia vera have 
been known to live for m any years without 
com plications, this is rare even with treatment. 
Vascular thrombosis is the most frequent 
com plication and haemorrhage is not unusual 
although the precise mechanism for this is not 
understood. In that the disease is one of later 
life, affected subjects may die of an unrelated 
condition. T h e  terminal picture of the dis­
order may be myelofibrosis, a leukaemoid 
reaction which resembles chronic myeloid 
leukaemia, or acute leukaemia. Untreated the 
mean survival is about five years from the time 
of diagnosis (Lancet 1965). T h e  course of 
secondary polycythaem ia depends largely on 
the underlying cause.
TREATMENT
E xcept in polycythaem ia vera there is little 
evidence that therapy is required in the other 
conditions in' this group. Even though the
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blood viscosity will be raised in these there is 
little evidence that this alone requires therapy 
and thus, for exam ple, vascular phenomena 
are said on the whole to be unusual in the 
secondary physiological polyeythaemia of high 
altitude (Russell and C onley 1964). T h e 
situation may, however, be different where 
there is already a predisposition to vascular 
disease.
In polyeythaemia vera some form of treat­
m ent is required. In particular treatment 
reduces the incidence of vascular accidents and 
the life expectancy is thought to be prolonged 
to about 13  years from tire time of diagnosis 
(M assouredis and Lawrence 1957).
V enesection is the more frequently used 
form of treatment and by itself may produce 
a remission lasting several months. T h is is, 
however, unusual and when it is required more 
often than once in two months resort should 
be made to some other form of therapy. It 
is of particular value either alone or in con­
junction with other treatment in a surgical 
em ergency, for the rapid relief of symptoms 
and in patients not responding to or suffering 
from some com plication of other therapy such 
as throm bocytopaenia. F ive hundred m illi­
litres of blood should be removed on alternate 
days.
T h e  alternative to phlebotom y is some form 
of marrow depressant or a haem olytic agent 
such as phenylhydrazine . T h e  latter drug does 
nothing to remedy the thrombocytosis and 
this and its toxicity make it very little  used 
nowadays. T h e  most popular marrow depress­
ant has for m any years been the isotope P32. 
T h is is easily administered usually intravenous­
ly but it can be given orally, has a relatively 
short h alf life of 14  days, is a /3 em itter and 
irradiates the marrow tissues by being incorpor­
ated into the actively dividing marrow cells 
and then into the bones as calcium phosphate. 
Radiation sickness docs not occur and marrow 
depression is unusual. I f  one defines a 
remission as the disappearance of symptoms 
and the return of the blood counts to normal 
for at least six m onths, 84%  of patients have 
a full remission, 50%  requiring one dose only 
and less than 10 %  more than two doses (Szur 
et al 1959). Four per cent, however, fail to 
rem it after three injections and 13 %  have 
partial remissions only. T h e  average remission 
is of the order of two years though the range 
is considerable.
T h e  main objections to P 32 are the danger 
of thrombocytopaenia or pancytopaenia and
that it is thought to increase the incidence of 
acute leukaemia. In experienced hands the 
form er is not a real problem but this does not 
appear to be so with the latter. T h e  incidence 
of acute leukaemia was initially reported raised 
by Lawrence in 1955 and more recently Modan 
and Lilienfeld  (1964) have put it at up at over 
1 1  per cent. It is said, however, that acute 
leukaemia is merely the natural progression of 
the disease and becomes more obvious when 
survival is prolonged (Osgood 1964) and some 
well authenticated cases of acute leukaemia 
occurring in lion-irradiated subjects have been 
reported (Szur et al 1959). Nonetheless a 
recent report of chromosomal abnormalities in 
pa tients who received P32 is disturbing (Mac- 
diarmid 1965) and though their relevance has 
been challenged (M illard 1965) they recollect 
the findings of C ourt Brown and Abbatt (1955) 
of chromosomal abnormalities in patients 
irradiated for ankylosing spondylitis in whom 
an increased incidence of acute leukaemia is 
accepted.
T h e  main deficiency until recently has been 
the lack of a series of patients treated by other 
than P 32 but a recent scries from Manchester 
of 12 7  patients treated with cytotoxic drugs 
remedies this (Perkins et al 1964). T w o points 
in particular are of interest. F irstly none of 
these patients developed acute leukaemia, 
those patients not dying of some complication 
or intercurrent disease developing either 
myelofibrosis or a leukaemoid reaction 
sim ulating chronic myeloid leukaemia but 
distinguished from this by the absence of 
the Philadelphia chromosome and the normal 
alkaline phosphatase reaction. Secondly the 
mean survival was the same as for patients 
treated with P32 i.e. about 13  years (Perkins et 
al 1964; Hainan and Russell 1965).
T h e  drugs used in the main were thiotepa, 
busulphan and the folic acid antagonist 
pyrim etham ine the last two being consider­
ed the drugs of choice. Though a relatively 
small dose of pyrim etham ine was used (25mgs 
daily) 30%  of patients had complications in 
the form of megaloblastic anaemia and throm- 
bocy topaenia, though anorexia, nausea, buccal 
ulceration and exfoliative dermatitis could 
occur. These of course are readily reversible 
w ith folic acid but treatment necessitates close 
supervision. Rem issions were of the order of 
10 -12  m onths. Susulphan was given in a dose 
of 2-4mgs daily with a m aintenance dose of 
2mgs once or twice weekly, i.e. doses tended to 
be smaller than those used in the treatment
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o f chronic myeloid leaukaemia. Thrombo- 
cytopaenia was a problem and 8 of 18 patients 
did not respond. Six had remissions of 12-30 
months.
On the whole the experience of drug therapy 
appears to be that it is more difficult to apply,
necessitates more supervision and that re­
missions arc shorter. Since the survival of 
patients on drugs is in general similar to that 
of those on P 32 it does not seem to matter what 
one uses providing one uses something but it 
is possibly wiser to avoid P32 in the younger 
patient with polycythaemia vera.
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